High-dose chemotherapy and autologous stem cell transplant in women with de novo chemosensitive metastatic breast cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 27, Issue 3, 2004, Pages 250-255

  Stemmer, Salomon M ^a,b   Hardan, Izhar ^a   Brenner, Harry J ^a   Rizel, Shulamith ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

Author keywords

Chemosensitive; High dose chemotherapy; Stage IV breast cancer at presentation

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; MELPHALAN; MORPHINE; NAVELBINE; PACLITAXEL; PROGESTERONE RECEPTOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA; TOPOTECAN;

ADULT; ANEMIA; ANTIBIOTIC PROPHYLAXIS; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BACTEREMIA; BONE MARROW METASTASIS; BONE MARROW TOXICITY; BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; DIARRHEA; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FEMALE; HERPES SIMPLEX; HUMAN; INFECTION; LIVER METASTASIS; LUNG METASTASIS; LUNG TOXICITY; LYMPH NODE METASTASIS; METASTASIS; MUCOSA INFLAMMATION; NEUTROPENIA; PARTIAL MASTECTOMY; PROGNOSIS; SEPSIS; SOFT TISSUE METASTASIS; THROMBOCYTOPENIA;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARBOPLATIN; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROSPECTIVE STUDIES; REMISSION INDUCTION; SURVIVAL ANALYSIS; THIOTEPA; TRANSPLANTATION, AUTOLOGOUS;

EID: 2942532115     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.coc.0000093436.16710.e9     Document Type: Article

References (14)

1. Ellis MJ, Hayes DF, Lippman ME. Treatment of metastatic breast cancer. In: Harris JR, ed. Diseases of the Breast, ed 2. Philadelphia: Lippincott Williams & Wilkins; 2000:749-797.
2. Stadtmauer EA, O'Neill A, Goldstein LJ, et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N Engl J Med. 2000;342:1069-1076.
3. Rowlings PA, Williams SF, Antman KH, et al. Factors correlated with progression free survival after high dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer. JAMA, 1999; 282:1335-1343.
4. Fleming ID, Cooper JS, Henson DE, et al., eds. AJCC Staging Manual, 5th ed. Philadelphia: Lippincott-Raven; 1997.
5. Antman K, Ayash L, Elias A, et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol. 1992;10:102-110.
6. Antman KH, Rowlings PA, Vaughan WP, et al. High-dose chemotherapy with autologous hematopoietic stem cell support for breast cancer in North America. J Clin Oncol. 1997;15:1870-1879.
7. Peters WP, Shpall EJ, Jones RB, et al. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol. 1988;6:1368-1376.
8. Vaughan WP, Reed EC, Edwards B, Kessinger A. High-dose cyclophosphamide, thiotepa and hydroxyurea with autologous hematopoietic stem cell rescue: an effective consolidation chemotherapy regimen for early metastatic breast cancer. Bone Marrow Transplant. 1994;13:619-624.
9. Elias AD, Richardson P, Avigan D, et al. A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer: sequential phase III studies. Bone Marrow Transplantation. 2001;28:447-454.
10. Rahman ZU, Frye DK, Buzdar AU, et al. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol. 1997;15:3171-3177.
11. Greenberg PA, Hortobagyi GN, Smith TL, et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol. 1996;14:2197-2205.
12. Abraham R, Nagy T, Goss PE, Crump M. High dose chemotherapy and autologous blood stem cell support in women with breast carcinoma and isolated supraclavicular lymph node metastases. Cancer. 2000;88:790-795.
13. Weaver CH, West WH, Schwartzberg LS, et al. Induction, mobilization of peripheral blood stem cells (PBSC), high-dose chemotherapy and PBSC infusion in patients with untreated stage IV breast cancer: outcomes by intent to treat analyses. Bone Marrow Transplant. 1997;19:661-670.
14. Holland HK, Dix SP, Geller RB, et al. Minimal toxicity and mortality in high-risk breast cancer patients receiving high dose cyclophosphamide, thiotepa and carboplatin plus autologous marrow/stem cell transplantation and comprehensive supportive care. J Clin Oncol. 1996;14:1156-1164.